Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Glucotrack (Nasdaq: GCTK) reported 2025 results and development progress on its fully implantable continuous blood glucose monitoring (CBGM) platform. The company received three USPTO patents, completed a $4.0 million private placement, held cash of $7.4 million at year-end, and plans an IDE filing in Q2 2026 to support a U.S. clinical trial in H2 2026.
Full‑year 2025 R&D was $9.8M, G&A $6.3M, and net loss was $19.4M versus $22.6M in 2024. An Australian multicenter feasibility study is underway.
Positive
- Three USPTO patents issued for implantable CBGM technology
- Initiated multicenter feasibility study in Australia for CBGM
- Net loss improved to $19.4M from $22.6M (2024)
- Year-end cash of $7.4M, up from $5.6M
Negative
- Operating cash used of $15.3M in 2025
- General & Administrative expense rose 24% to $6.3M in 2025
- Private placement included warrants covering up to 2,067,182 shares (potential dilution)
News Market Reaction – GCTK
On the day this news was published, GCTK declined 14.11%, reflecting a significant negative market reaction. Argus tracked a trough of -32.1% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $217K from the company's valuation, bringing the market cap to $1.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GCTK fell 9.16% with sector peers also weak; momentum data show 3 peers moving down (median move about -2.4%) and only 1 up, pointing to broader pressure on medical instrument names alongside company-specific factors.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Negative | -8.6% | Reported higher net loss with new financing and clinical progress updates. |
| Aug 14 | Q2 2025 earnings | Positive | +0.9% | Detailed CBGM progress, strong cash of $9.6M, and feasibility study plans. |
| May 14 | Q1 2025 earnings | Neutral | +0.1% | Showed higher R&D and net loss but improved cash to fund 2025 plan. |
| Mar 31 | FY 2024 results | Positive | +28.9% | Transformative year with first human CBGM study and significant new funding. |
Earnings-related releases have generally seen stock moves that align with the tone of updates, with three modest reactions and one large upside move when 2024 results were reported.
Across prior earnings updates from March 2024 through November 2025, Glucotrack consistently paired financial results with CBGM clinical milestones and financing actions. Cash levels moved from $5.6M at year-end 2024 to $9.6M mid-2025 and then to $7.9M by Q3 2025, supported by equity and note financings. Each earnings report reinforced the transition toward multicenter feasibility studies and IDE submission plans. Today’s full-year 2025 report continues this pattern, highlighting R&D spend, cash runway into 2026, and preparation for U.S. trials.
Historical Comparison
In the past year, GCTK issued 4 earnings updates with an average move of 5.33%. Reactions usually tracked the tone of financing and CBGM progress disclosed.
Earnings releases have charted CBGM’s path from first human data through feasibility studies toward IDE submission and U.S. clinical trials.
Regulatory & Risk Context
An effective S-3 from Jan 13, 2026 registers 3,224,803 shares for resale from December 2025 private placement warrants, equal to about 354% of the 910,688 shares then outstanding. Glucotrack receives no proceeds from these resales, but the large registered block represents a significant potential overhang and dilution source for existing holders.
Market Pulse Summary
The stock dropped -14.1% in the session following this news. A negative reaction despite operational progress fits a pattern where Glucotrack’s news often coincided with pressure on the stock, including prior earnings moves such as -8.64% and other dilutive financings. The full-year 2025 update still shows a $19.4M net loss and substantial cash use, while an effective S-3 registering 3,224,803 resale shares creates notable overhang. High sector-wide weakness and existing overhang risk could have amplified selling pressure.
Key Terms
investigational device exemption regulatory
ide regulatory
u.s. food and drug administration regulatory
fda regulatory
uspto regulatory
continuous blood glucose monitoring medical
private placement financial
warrants financial
AI-generated analysis. Not financial advice.
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026
US Patent and Trademark Office (USPTO) issued patents for Glucotrack’s implantable
continuous blood glucose monitoring (CBGM) technology, strengthening the Company’s
intellectual property portfolio
Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2025.
“In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation. We strengthened our competitive position with three new patents issued by the USPTO and continued to work closely with the FDA on alignment as we progress toward securing IDE approval and initiating our U.S. clinical study program of our CBGM product,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We entered 2026 with strong momentum and a reinforced balance sheet, positioning the Company to execute on important development and regulatory milestones.”
Fourth Quarter 2025 & Recent Highlights
Corporate Highlights
| ● | Completed |
| ○ | In December 2025, the Company entered into a securities purchase agreement with a single institutional investor for the sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at a combined effective price of | |
| ○ | The Company expects to use the net proceeds from the offering for working capital and general corporate purposes. |
| ● | Strengthened the Company’s intellectual property portfolio for novel implantable CBGM platform. The three patents protect key technologies in Glucotrack’s CBGM system, a long-term implantable device designed for three-year sensor longevity, including proprietary sensor chemistry, intravascular lead design, and low-power electronics. Together, these innovations bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices. |
| ● | Appointed Usman Latif, MD, MBA, to the Company’s clinical advisory team. Dr. Latif is a prominent pain management specialist and opinion leader with deep expertise in neuromodulation and treatment of painful diabetic neuropathy (PDN). This expertise will be invaluable as the Company advances its epidural glucose monitoring applications and integrates disease and device management solutions for PDN patients. | |
| ● | The Company held its second Patient Advisory Board (PAB) meeting during which patients provided feedback on the mobile application Glucotrack is developing to accompany its CBGM technology. |
Advanced Product and Clinical Development
| ● | The Company initiated a long-term, multicenter feasibility study in Australia to evaluate the CBGM product performance and safety. The first phase of the clinical study provided early product learnings about how the complexity of certain health conditions may impact study eligibility as well as identified certain product improvements. Consequently, the Company is expediting discussions with the U.S. Food and Drug Administration (FDA) regarding our planned U.S. clinical trial program that we expect to launch in the 2nd half of 2026, subject to FDA approval of our Investigational Device Exemption (“IDE”) submission expected to be filed in Second Quarter 2026. | |
| ● | Presented at the 2025 Diabetes Technology Meeting held on October 28th, 2025 on the importance of an integrated approach to diabetes management and highlighting how combining continuous glucose monitoring with existing implantable technologies can enable one implant to address multiple chronic conditions—redefining care for patients managing both diabetes and other chronic conditions. The presentation showcased the company’s preclinical work in epidural glucose monitoring which, when combined with spinal cord stimulation technologies, has the potential to offer integrated device and disease management for patients living with PDN. |
Anticipated Milestones
| ● | Submitting the Company’s IDE to the FDA in Second Quarter 2026 to initiate an initial human clinical Feasibility Study of the CBGM product, subject to current agency response timelines. | |
| ● | Presenting clinical data demonstrating the safety and accuracy of the CBGM product at additional industry conferences. | |
| ● | Further expanding Advisory Boards with world-renowned experts in endocrinology and cardiology and others essential to the diabetes community. | |
| ● | Continuing to gain insight from patients living with diabetes on current management challenges and get feedback on Glucotrack’s product development and commercialization strategies through additional PAB meetings. |
Financial Results for the Year Ended December 31, 2025
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and administrative expenses were
Net Loss: Net loss for the full year 2025 was
Cash Position: Cash and cash equivalents as of December 31, 2025, were
Based on current plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its 2026 operating plan by the end of Spring allowing for its IDE submission and initiate U.S. human clinical trials in 2026.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contacts:
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
GLUCOTRACK INC.
CONSOLIDATED BALANCE SHEETS
| In thousands of US dollars (except stock data) | ||||||||
| December 31, 2025 | December 31, 2024 | |||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 7,383 | $ | 5,617 | ||||
| Other current assets | 284 | 151 | ||||||
| Total current assets | 7,667 | 5,768 | ||||||
| Operating lease right-of-use asset, net | 33 | 59 | ||||||
| Property and equipment, net | 138 | 95 | ||||||
| Restricted cash | - | 10 | ||||||
| TOTAL ASSETS | $ | 7,838 | $ | 5,932 | ||||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 1,317 | $ | 992 | ||||
| Operating lease liability, current | 28 | 26 | ||||||
| Promissory notes | 3,182 | - | ||||||
| Convertible promissory notes | - | 5 | ||||||
| Other current liabilities | 246 | 252 | ||||||
| Total current liabilities | 4,773 | 1,275 | ||||||
| Non-Current Liabilities | ||||||||
| Derivative financial liabilities | 1 | 17,421 | ||||||
| Operating lease liability, non-current | 5 | 33 | ||||||
| Loans from stockholders | 231 | 203 | ||||||
| Total liabilities | 5,010 | 18,932 | ||||||
| Commitments and contingent liabilities | ||||||||
| Stockholders’ (Deficit) Equity | ||||||||
| Common Stock of | ||||||||
| 250,000,000 shares authorized as of December 31, 2025 and 100,000,000 shares authorized as of December 31, 2024; 910,688 and 13,409 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 151,080 | 119,229 | ||||||
| Receipts on account of shares | 3,544 | 228 | ||||||
| Accumulated other comprehensive income | 41 | (8 | ) | |||||
| Accumulated deficit | (151,838 | ) | (132,450 | ) | ||||
| Total stockholders’ (deficit) equity | 2,828 | (13,000 | ) | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | $ | 7,838 | $ | 5,932 | ||||
GLUCOTRACK INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| In thousands of US dollars (except stock and per stock amounts) | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development expenses | $ | 9,813 | $ | 9,499 | ||||
| General and administrative expenses | 6,277 | 5,048 | ||||||
| Total operating expenses | 16,090 | 14,547 | ||||||
| Loss from operations | 16,090 | 14,547 | ||||||
| Other income (expense): | ||||||||
| Other (income) expense | (26 | ) | (14 | ) | ||||
| Change in fair value of derivative liability | 3,267 | 798 | ||||||
| Loss on equity issuance | - | 1,925 | ||||||
| Loss on settlement of liabilities | - | 4,758 | ||||||
| Finance expense, net | 57 | 583 | ||||||
| Total other income | 3,298 | 8,050 | ||||||
| Net loss | 19,388 | 22,597 | ||||||
| Other comprehensive loss: | ||||||||
| Foreign currency translation adjustment | (49 | ) | (24 | ) | ||||
| Comprehensive loss | $ | 19,339 | $ | 22,573 | ||||
| Basic and diluted loss per share | $ | 31.22 | $ | 4,106 | ||||
| Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share | 621,094 | 5,503 | ||||||
FAQ
What is Glucotrack (GCTK) planning for its IDE filing and U.S. clinical trial timeline?
How much cash did Glucotrack (GCTK) report at December 31, 2025 and what financed the increase?
What were Glucotrack's (GCTK) 2025 R&D and net loss figures and how did they change from 2024?
What intellectual property progress did Glucotrack (GCTK) report on its implantable CBGM platform?
What financing did Glucotrack (GCTK) complete in December 2025 and what are the terms?
